Otosclerosis

Otosclerosis is a disorder of abnormal bone remodeling confined to the bony labyrinth (otic capsule) of the inner ear, most commonly causing the stapes footplate to become fixed. It is the leading cause of progressive conductive hearing loss in young adults in developed countries, often beginning in the second or third decade of life and progressing insidiously over years. Surgical treatment — stapedectomy or stapedotomy — produces excellent outcomes in suitable candidates, with the vast majority of patients achieving near-normal hearing.

Table of Contents

  1. What Is Otosclerosis?
  2. Genetics and Epidemiology
  3. Pathophysiology
  4. Symptoms and Clinical Presentation
  5. Audiogram Findings
  6. Schwartze Sign and Examination
  7. Imaging
  8. Cochlear Otosclerosis
  9. Surgical Treatment: Stapedectomy and Stapedotomy
  10. Non-Surgical Management
  11. Sodium Fluoride Therapy
  12. Pregnancy and Hormonal Factors
  13. References & Research
  14. Featured Videos

What Is Otosclerosis?

Otosclerosis (from Greek: "hard ear") describes a process in which the normally dense enchondral bone of the otic capsule undergoes focal remodeling, with replacement of compact lamellar bone by spongy, highly vascular woven bone — a process termed otospongiosis. The most clinically significant focus is at the fissula ante fenestram, a small cleft anterior to the oval window, which brings the abnormal bone directly into contact with the stapes footplate.

As the otosclerotic focus expands, it progressively immobilizes the stapes footplate within the oval window. The stapes is the innermost of the three ossicles (malleus, incus, stapes) and is responsible for transmitting sound vibrations from the tympanic membrane through the oval window into the fluid-filled cochlea. When the footplate is fixed, this mechanical transmission is impaired, producing conductive hearing loss that worsens over time.

The condition was first clearly described by Valsalva and later studied in depth by Adam Politzer and Johannes Kessel in the 19th century. Julius Lempert's fenestration operation in 1938 and John Shea's development of the modern stapedectomy in 1956 transformed otosclerosis from an inevitably progressive deafness to a highly surgically correctable condition.

Genetics and Epidemiology

Otosclerosis has a complex genetic basis with incomplete penetrance, making its inheritance pattern difficult to characterize definitively.

Genetic Factors

Epidemiology

Pathophysiology

The otic capsule is one of the few sites in the adult human body that normally does not undergo bone remodeling — a property called enchondral ossification stability. In otosclerosis, this protective property breaks down in focal sites.

The Remodeling Process

The pathological sequence begins with osteoclastic resorption of normal enchondral bone, followed by deposition of woven, immature bone with abundant vascular spaces (the "otospongiotic" phase, associated with active disease). Over time this is replaced by dense sclerotic bone. The active phase is characterized by increased vascularity, seen clinically as the Schwartze sign (see below) and histologically as prominent vascular spaces lined by endothelium.

Measles Virus Hypothesis

A widely investigated hypothesis proposes that persistent measles virus infection of osteoblasts in genetically susceptible individuals triggers the abnormal remodeling cascade. Measles virus RNA has been identified in otosclerotic footplates in multiple studies. The near-universal measles vaccination programs in developed countries are associated with a declining incidence of otosclerosis, lending epidemiological support to this hypothesis, though it remains under investigation.

Fluoride and Bone Metabolism

Low dietary fluoride intake and areas with fluoride-deficient water supplies have been correlated with higher otosclerosis prevalence in some studies. Fluoride is known to inhibit osteoclast activity and stabilize hydroxyapatite crystals, potentially protecting against the abnormal remodeling of otosclerosis. This forms the mechanistic basis for sodium fluoride therapy (see below).

Symptoms and Clinical Presentation

The onset of otosclerosis is typically insidious, with patients often unable to identify when their hearing began to decline. Several characteristic features help distinguish it clinically:

Progressive Conductive Hearing Loss

The primary and defining symptom is slowly progressive hearing loss, usually beginning unilaterally and becoming bilateral over years in most patients. Patients typically report difficulty hearing soft sounds (low-volume speech, whispers) and preferring quieter environments, in contrast to sensorineural hearing loss patients who often have particular difficulty in background noise.

Paracusis Willisii

A classic and historically well-known feature of otosclerosis is paracusis Willisii — paradoxically better hearing in noisy environments. Because otosclerosis causes conductive hearing loss, ambient background noise masks other speakers less effectively for the patient (who hears the noise at a lower relative level through their impaired conductive system), while normal-hearing people are more distracted by it and tend to raise their voices. This counterintuitive phenomenon disappears as sensorineural components develop.

Tinnitus

Tinnitus, usually low-frequency and described as a hum or buzz, is present in approximately 75% of patients. It may precede or accompany the hearing loss. The character of tinnitus may shift as disease progresses from a predominantly conductive to mixed hearing loss.

Vestibular Symptoms

Mild vestibular symptoms — unsteadiness, vague dizziness without true vertigo — are present in a minority of patients, thought to arise from invasion of perilymph spaces by otosclerotic bone or secondary hydropic changes.

Audiogram Findings

Audiometry in otosclerosis produces a characteristic pattern that is diagnostic when all elements are present:

Air-Bone Gap

The fundamental finding is an air-bone gap: air conduction thresholds are elevated (hearing loss), while bone conduction thresholds are initially normal or near-normal. This gap reflects pure conductive hearing loss from stapes fixation — sound can still be conducted through bone to the cochlea, but airborne sound transmission through the ossicular chain is impaired.

Carhart's Notch

A diagnostically important and initially puzzling finding is the Carhart's notch — a characteristic dip in bone conduction thresholds at 2 kHz (with smaller dips at 500 Hz and 4 kHz). Named for Raymond Carhart who described it in 1950, this is a mechanical artifact of stapes fixation rather than true sensorineural hearing loss. The stapes resonates at approximately 2 kHz; when it is fixed, this resonance is lost, artifactually reducing the bone conduction threshold at that frequency. The Carhart's notch typically disappears after successful stapedectomy, confirming its mechanical origin.

Tympanometry

Tympanometry shows a flat (type As or type A) tympanogram with reduced or absent stapedial reflexes. The reduced compliance on tympanometry differentiates otosclerosis from middle ear pathology (effusion would show type B tympanogram). Acoustic reflexes are absent or elevated in threshold due to stapes fixation.

Late-Stage Audiogram

As cochlear otosclerosis develops, bone conduction thresholds deteriorate across all frequencies, producing a mixed (combined conductive + sensorineural) hearing loss. In advanced cochlear involvement, the air-bone gap may narrow or close as both components progress.

Schwartze Sign and Examination

The external ear canal and tympanic membrane appear normal in otosclerosis — there is no visible middle ear effusion, perforation, or ossicular malformation visible through the drum. This normal otoscopic appearance in a patient with progressive conductive hearing loss and absent reflexes is itself an important clue pointing toward otosclerosis.

Schwartze Sign

In approximately 10–15% of patients with active, vascular otosclerosis (otospongiosis), a reddish-pink or "flamingo pink" blush is visible through the translucent tympanic membrane, most prominent over the promontory. This is the Schwartze sign (also called the flamingo pink sign), named for Hermann Hugo Rudolf Schwartze who described it in the 19th century. It reflects the increased vascularity of actively remodeling otosclerotic bone underlying the promontory. Its presence indicates active disease and may be associated with more rapid progression. It is not present in all patients and may resolve as disease transitions from the active otospongiotic phase to the sclerotic phase.

Imaging

Imaging is not required for the diagnosis of typical otosclerosis, which is made clinically and audiometrically. However, high-resolution CT scanning of the temporal bones is valuable in specific circumstances:

On CT, active otosclerotic foci appear as hypodense (less dense than normal otic capsule) halos around the cochlea, particularly at the fissula ante fenestram. The double-ring sign — a halo of hypodensity surrounding the cochlea — indicates cochlear otosclerosis. MRI is not routinely used but can demonstrate enhancement of active foci on contrast sequences.

Cochlear Otosclerosis

When otosclerotic lesions extend beyond the stapes region to invade the cochlea, an additional sensorineural component of hearing loss develops. This is called cochlear otosclerosis (or retrofenestral otosclerosis).

The mechanisms of cochlear damage include:

Cochlear otosclerosis produces high-frequency sensorineural hearing loss that is superimposed on the conductive component. Once established, the sensorineural component is not reversed by stapedectomy (which corrects only the conductive component). Cochlear otosclerosis in its severe form can progress to profound sensorineural deafness, at which point cochlear implantation may be the only remaining rehabilitative option. The presence of a cochlear otosclerosis halo on CT may actually facilitate cochlear implant electrode insertion, as the modified bone can provide a pathway.

Surgical Treatment: Stapedectomy and Stapedotomy

Surgery is the definitive treatment for otosclerosis and produces excellent outcomes in suitable candidates. It is one of the most successful elective ear operations in otolaryngology.

Stapedectomy

The original procedure developed by John Shea in 1956 involves removal of the entire stapes superstructure and footplate, followed by sealing the oval window with a tissue graft (vein, fat, or perichondrium) and interposing a prosthetic piston between the incus long process and the oval window. Outcomes with stapedectomy are excellent: approximately 90–95% of patients achieve closure of the air-bone gap to within 10 dB, with many achieving normal or near-normal hearing.

Stapedotomy

The modern preferred technique is stapedotomy (small fenestra technique), in which only a small hole (0.4–0.8 mm) is made in the fixed footplate — either manually with a microdrill, laser (CO2, KTP, Er:YAG), or combined laser-manual technique — and a Teflon or titanium piston prosthesis is inserted through the fenestration and attached to the incus. Stapedotomy has largely replaced total stapedectomy because it:

Prosthesis Options

Modern prostheses include Teflon (polytetrafluoroethylene) pistons, titanium clip pistons, and nitinol (nickel-titanium) memory alloy pistons. Titanium and nitinol prostheses are MRI-compatible and increasingly preferred. The standard piston length is 4.5 mm (range 4.0–5.0 mm depending on anatomy), and diameter 0.4–0.6 mm.

Surgical Outcomes and Risks

Overall outcomes: approximately 95% of patients achieve an air-bone gap of 10 dB or less; approximately 85% achieve closure to within 5 dB. Serious risks include sensorineural hearing loss (approximately 1–2%), facial nerve injury (rare, less than 1%), and perilymph fistula. Patients are counseled that a small risk exists of worsening hearing, potentially to profound levels.

Candidacy Criteria

Ideal candidates have: air-bone gap of 20 dB or greater; good bone conduction thresholds (indicating cochlear reserve); unilateral or bilateral disease with one ear operated first; and no significant medical contraindications to general or local anesthesia. Surgery on the better-hearing ear is approached more cautiously.

Non-Surgical Management

For patients who decline surgery, are not surgical candidates, or in whom the hearing loss is mild, hearing aids remain an effective option. Otosclerosis causes a conductive hearing loss, which is generally well-amplified by conventional hearing aids. As cochlear otosclerosis develops and a sensorineural component emerges, hearing aid fitting becomes more complex but remains valuable. Bone-anchored hearing devices (BAHA) are an option for patients in whom conventional amplification is insufficient or poorly tolerated.

Sodium Fluoride Therapy

Sodium fluoride has been used as a medical therapy to slow the progression of otosclerosis, particularly to prevent cochlear extension and the development of sensorineural hearing loss. The rationale is biochemical: fluoride ions substitute for hydroxyl groups in hydroxyapatite, forming fluorapatite, which is more resistant to osteoclastic resorption. Fluoride also inhibits lysosomal enzyme activity in osteoclasts.

Clinical Evidence

The evidence base for sodium fluoride in otosclerosis is limited by the lack of large randomized controlled trials. Several observational studies and case series from the 1970s–1990s suggested that fluoride at doses of 20–60 mg per day (as sodium fluoride) could stabilize or slow the sensorineural progression of cochlear otosclerosis. The most widely cited recommendation is 20 mg of sodium fluoride twice daily with calcium supplements (to prevent fluoride-induced hypocalcemia and bone toxicity).

Limitations and Adverse Effects

Sodium fluoride does not reverse established stapes fixation or existing sensorineural hearing loss; its role is preventive against further deterioration. High doses carry risks of skeletal fluorosis, gastric irritation, and, paradoxically, dental fluorosis in children. It is contraindicated in pregnancy and renal impairment. Given the limited evidence and potential toxicity, many otologists recommend reserving fluoride therapy for patients with documented active cochlear otosclerosis (positive CT halo sign + progressive bone conduction loss) rather than using it universally.

Pregnancy and Hormonal Factors

The well-documented acceleration of otosclerosis during pregnancy represents one of the strongest lines of evidence for a hormonal component to disease activity. Multiple pregnancies appear to accelerate both the conductive and sensorineural components of hearing loss. The proposed mechanisms include:

The two-fold higher prevalence in women compared to men, combined with pregnancy acceleration, has led to investigations of estrogen receptor expression in otosclerotic bone. Higher estrogen receptor density has been demonstrated in otosclerotic foci compared to normal otic capsule. Some authors have proposed that low-dose estrogen-containing oral contraceptives might similarly accelerate disease, though the evidence is less clear than for pregnancy. Women with known or suspected otosclerosis who are considering pregnancy should discuss the potential for hearing deterioration with their otolaryngologist in advance.

References & Research

Key Research Papers

  1. Declau F, Van Spaendonck M, Timmermans JP, et al. Prevalence of histologic otosclerosis: an unbiased temporal bone study in Caucasians. Adv Otorhinolaryngol. 2007;65:6-16. PMID 17245022
  2. Babighian G. Otosclerosis: epidemiology, clues to etiology, and long-term results of stapedectomy. Otolaryngol Clin North Am. 1993;26(3):305-316. PMID 8321580
  3. Karosi T, Konya J, Szabo LZ, Sziklai I. Measles virus prevalence in otosclerotic footplates with clinical correlation. Laryngoscope. 2004;114(8):1346-1351. PMID 15280706
  4. Shea JJ. Fenestration of the oval window. Ann Otol Rhinol Laryngol. 1958;67(4):932-951. PMID 13608760
  5. Kisilevsky VE, Bailie NA, Halik JJ. Bilateral stapedotomy outcomes in the management of otosclerosis. J Laryngol Otol. 2009;123(7):724-729. PMID 19207934
  6. Merkus P, Van Loon MC, Smit CF, Smits C, De Cock AF, Hensen EF. Decision making in advanced otosclerosis: an evidence-based strategy. Laryngoscope. 2011;121(9):1935-1941. PMID 21800342
  7. Gristwood RE, Venables WN. Pregnancy and otosclerosis. Clin Otolaryngol Allied Sci. 1983;8(3):205-210. PMID 6861248
  8. Arnold W, Friedmann I. Otosclerosis — an inflammatory disease of the otic capsule of viral aetiology? J Laryngol Otol. 1988;102(10):865-871. PMID 3062148
  9. Perez R, De Wet Swanepoel H, Leibu R, Sichel JY. Revision stapes surgery: which factors determine the outcome? Otolaryngol Head Neck Surg. 2000;123(3):249-252. PMID 10964297
  10. Ramsay HA, Linthicum FH Jr. Mixed hearing loss in otosclerosis: indication for long-term follow-up. Am J Otol. 1994;15(4):536-539. PMID 7978892
  11. Cureoglu S, Baylan MY, Paparella MM. Cochlear otosclerosis. Curr Opin Otolaryngol Head Neck Surg. 2010;18(5):357-362. PMID 20601882
  12. Niedermeyer HP, Arnold W. Etiopathogenesis of otosclerosis. ORL J Otorhinolaryngol Relat Spec. 2002;64(2):114-119. PMID 12021480

Back to Table of Contents

Research Papers

The following PubMed topic searches retrieve current peer-reviewed literature on Otosclerosis. Each link opens a live PubMed query.

  1. Otosclerosis genetics OTSC
  2. Stapedotomy outcomes hearing
  3. Otosclerosis measles virus
  4. Cochlear otosclerosis sensorineural
  5. Carhart notch audiogram
  6. Stapedectomy prosthesis review
  7. Sodium fluoride otosclerosis treatment
  8. Otosclerosis pregnancy estrogen
  9. Otic capsule bone remodeling
  10. Laser stapedotomy CO2 KTP

Back to Table of Contents

Connections

Back to Table of Contents